Cefotaxime

Product Description

Cefotaxime injection is used to treat certain infections caused by bacteria including pneumonia and other lower respiratory tract (lung) infections; gonorrhea (a sexually transmitted disease); meningitis (infection of the membranes that surround the brain and spinal cord) and other brain and spinal cord infections; and abdominal (stomach area), female reproductive organs, skin, blood, bone, joint, and urinary tract infections. Cefotaxime injection may also be used before surgery, and during and after a cesarean section, in order to prevent the patient from getting an infection. Cefotaxime injection is in a class of medications called cephalosporin antibiotics. It works by killing bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a682765.html)

Mechanisms of Action: PBP Inhibitor,Cell Wall Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None